Back to top
more

Assertio (ASRT)

(Delayed Data from NSDQ)

$1.54 USD

1.54
1,655,415

-0.12 (-7.23%)

Updated Jul 15, 2024 04:00 PM ET

After-Market: $1.55 +0.01 (0.65%) 5:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?

Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates

Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Assertio (ASRT) Gains As Market Dips: What You Should Know

Assertio (ASRT) closed at $5.12 in the latest trading session, marking a +1.19% move from the prior day.

Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?

Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.

Assertio Holdings, Inc. (ASRT) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know

Assertio (ASRT) closed the most recent trading day at $5.10, moving +0.59% from the previous trading session.

Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?

Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.

Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?

On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.

Why Assertio (ASRT) Could Beat Earnings Estimates Again

Assertio (ASRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?

Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.

Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know

Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Assertio (ASRT) Gains As Market Dips: What You Should Know

Assertio (ASRT) closed the most recent trading day at $4.18, moving +1.95% from the previous trading session.

Assertio (ASRT) Gains As Market Dips: What You Should Know

In the latest trading session, Assertio (ASRT) closed at $4.02, marking a +0.25% move from the previous day.

Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know

Assertio (ASRT) closed at $4.06 in the latest trading session, marking a +1.25% move from the prior day.

Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics

Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as the Drug Industry Bets Big on Innovation

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.

Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe

Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.

Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know

Assertio (ASRT) closed the most recent trading day at $4.22, moving +1.44% from the previous trading session.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Boeing, Halliburton, Starbucks in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Are Medical Stocks Lagging Assertio (ASRT) This Year?

Here is how Assertio (ASRT) and Liquidia Technologies, Inc. (LQDA) have performed compared to their sector so far this year.

ASRT vs. ZTS: Which Stock Is the Better Value Option?

ASRT vs. ZTS: Which Stock Is the Better Value Option?

Ensign Group (ENSG) Rises 30% in 6 Months: More Room to Run?

Ensign Group (ENSG) is well-poised for improvement on growing revenues derived from catering to patients under Medicaid and Medicare programs. Solid cash flows are other tailwinds.